These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29266867)

  • 1. Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Wang T; Cheng C; Peng L; Gao M; Xi M; Rousseaux S; Khochbin S; Wang J; Mi J
    J Cell Mol Med; 2018 Mar; 22(3):1614-1626. PubMed ID: 29266867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
    J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo.
    Wahiduzzaman M; Ota A; Karnan S; Hanamura I; Mizuno S; Kanasugi J; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Takami A; Hosokawa Y
    Cancer Lett; 2018 Oct; 433():117-130. PubMed ID: 29944906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
    Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
    Bornhauser BC; Bonapace L; Lindholm D; Martinez R; Cario G; Schrappe M; Niggli FK; Schäfer BW; Bourquin JP
    Blood; 2007 Sep; 110(6):2084-91. PubMed ID: 17537996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.
    Morishita T; Hayakawa F; Sugimoto K; Iwase M; Yamamoto H; Hirano D; Kojima Y; Imoto N; Naoe T; Kiyoi H
    Oncotarget; 2016 Aug; 7(35):56241-56252. PubMed ID: 27494842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
    Short NJ; Kantarjian HM; Sasaki K; Ravandi F; Ko H; Cameron Yin C; Garcia-Manero G; Cortes JE; Garris R; O'Brien SM; Patel K; Khouri M; Thomas D; Jain N; Kadia TM; Daver NG; Benton CB; Issa GC; Konopleva M; Jabbour E
    Am J Hematol; 2017 Mar; 92(3):238-243. PubMed ID: 28006851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
    Haddad FG; Kourie HR; Saleh K
    Br J Haematol; 2023 Sep; 202(6):1084-1086. PubMed ID: 37525325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.
    Ito Y; Miyamoto T; Kamimura T; Aoki K; Henzan H; Aoki T; Shiratsuchi M; Kato K; Nagafuji K; Ogawa R; Eto T; Iwasaki H; Akashi K
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e47-54. PubMed ID: 25445469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
    Guo Y; Li Y; Xiang B; Huang XO; Ma HB; Wang FF; Gong YP
    Biochem J; 2017 Dec; 474(24):4153-4170. PubMed ID: 29046392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EVI-1 modulates arsenic trioxide induced apoptosis through JNK signalling pathway in leukemia cells.
    Lang W; Zhu J; Chen F; Cai J; Zhong J
    Exp Cell Res; 2019 Jan; 374(1):140-151. PubMed ID: 30472098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
    Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Li XY; Qian JJ; Yang M; Zhang Y; Wang SS; Meng HT; Yu WJ; Tong HY; Ye XJ; Jin J; Zhu HH
    Br J Haematol; 2020 Jun; 189(6):e231-e234. PubMed ID: 32314800
    [No Abstract]   [Full Text] [Related]  

  • 17. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib and low-intensity chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia in a child with Down syndrome.
    Hirabayashi S; Hasegawa D; Yamamoto K; Nishimura A; Hosoya Y; Shuo T; Kiyokawa N; Miura M; Takahashi N; Manabe A
    Pediatr Blood Cancer; 2019 May; 66(5):e27612. PubMed ID: 30663211
    [No Abstract]   [Full Text] [Related]  

  • 19. The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.
    Nathwani SM; Greene LM; Butini S; Campiani G; Williams DC; Samali A; Szegezdi E; Zisterer DM
    Int J Oncol; 2016 Jul; 49(1):74-88. PubMed ID: 27176505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
    Brattås MK; Reikvam H; Tvedt THA; Bruserud Ø
    Expert Opin Investig Drugs; 2019 May; 28(5):411-420. PubMed ID: 30916583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.